For temporally biphasic and multi-phasic local currents the sensitivity of these methods can be reduced through the cancellation of the accrued phase induced by positive and negative episodes of the neuronal current.
In circuit QED, ancilla measurement has been accomplished by coupling the qubit to photons passing through a resonator, and observing the accrued phase using homodyne detection [13].
Thus, characterizing the distributions of pharmacokinetic variables is a gradual process accrued during phase 2 and phase 3 of drug development, but it must continue into phase 4 to cover all relevant populations.
Forty-four paccrued accrued to Phase I or Phase II investigational therapy trials were simultaneously enrolled into a defined home care program focused on supportive care needs of the patient and family, as well as assessment of the toxicities of investigational therapy.
The authors compare favourably this regimen with results of third-line treatments in randomised phase III studies, while it can be admitted that the patients accrued in phase II studies inevitably are more selected.
The informatics workgroup created and published a library of EMR-based phenotyping algorithms accrued throughout phase I that is available to investigators outside of the eMERGE Network.
These figures indicate that these were indeed the patients with malignancies for which no effective standard treatments exist, or alternatively these patients were accrued into phase I trials containing at least one active approved anticancer agent.
4-point MACE were accrued from one phase 2 and seven phase 3 trials between 12 and 104 weeks in duration (including five 52-week and two 104-week trials) and one interim analysis of the on-going Canagliflozin Cardiovascular Assessment Study (CANVAS) trial.
Thus, an excited spin that moves away from its position at the start of a bipolar gradient (a pair of equally strong but oppositely directed gradients) will accrue a phase shift relative to one that stayed at its point of origin throughout the bipolar gradient.
On the basis of these promising results, a phase-II trial (BRIM 2, NCT00949702) is now fully accrued and a phase-III trial (BRIM3, NCT01006980) comparing PLX4032 to standard chemotherapy with the alkylating agent dacarbazine in untreated patients with BRAFV600E mutant metastatic melanoma is underway.
Ten patients were accrued to the phase I portion, which utilized an accelerated titration design.
